These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 23998723)
1. Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen? Karan D Immunotherapy; 2013 Sep; 5(9):907-10. PubMed ID: 23998723 [No Abstract] [Full Text] [Related]
2. Vaccine immunotherapy for prostate cancer: from mice to men. Lubaroff DM; Vaena D; Brown JA; Zehr P; Griffith KC; Brown E; Eastman J; Nepple K; Kattula A; Williams RD Immunol Res; 2014 Aug; 59(1-3):229-35. PubMed ID: 24847764 [TBL] [Abstract][Full Text] [Related]
3. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018 [TBL] [Abstract][Full Text] [Related]
4. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer vaccines in combination with additional treatment modalities. Uhlman MA; Bing MT; Lubaroff DM Immunol Res; 2014 Aug; 59(1-3):236-42. PubMed ID: 24838261 [TBL] [Abstract][Full Text] [Related]
8. Dramatic and prolonged PSA response after retreatment with a PSA vaccine. Rojan A; Funches R; Regan MM; Gulley JL; Bubley GJ Clin Genitourin Cancer; 2013 Sep; 11(3):362-4. PubMed ID: 23791437 [No Abstract] [Full Text] [Related]
9. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049 [TBL] [Abstract][Full Text] [Related]
10. Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy. Yan F; Li X; Li N; Zhang R; Wang Q; Ru Y; Hao X; Ni J; Wang H; Wu G Cancer Lett; 2017 Aug; 402():32-42. PubMed ID: 28529067 [TBL] [Abstract][Full Text] [Related]
11. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Beinart G; Rini BI; Weinberg V; Small EJ Clin Prostate Cancer; 2005 Jun; 4(1):55-60. PubMed ID: 15992463 [TBL] [Abstract][Full Text] [Related]
12. Advances in prostate cancer immunotherapy. Havranek EG; Whelan MA; Greenhalgh R; Dalgleish AG; Pandha H Surg Oncol; 2002 Jun; 11(1-2):35-45. PubMed ID: 12031866 [TBL] [Abstract][Full Text] [Related]
13. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Muthumani K; Marnin L; Kudchodkar SB; Perales-Puchalt A; Choi H; Agarwal S; Scott VL; Reuschel EL; Zaidi FI; Duperret EK; Wise MC; Kraynyak KA; Ugen KE; Sardesai NY; Joseph Kim J; Weiner DB Cancer Immunol Immunother; 2017 Dec; 66(12):1577-1588. PubMed ID: 28819703 [TBL] [Abstract][Full Text] [Related]
14. Development of PROSTVAC immunotherapy in prostate cancer. Singh P; Pal SK; Alex A; Agarwal N Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for prostate cancer. Fong L; Small EJ Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412 [TBL] [Abstract][Full Text] [Related]